Home LiteratureArticle Details
PMID: 11901192 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection.

The Journal of clinical investigation ·Vol. 109 ·No. 6 ·2002-03-00 ·Pages 837-43

Altfeld M, van Lunzen J, Frahm N, Yu XG, Schneider C, Eldridge RL, Feeney ME, Meyer-Olson D, Stellbrink HJ, Walker BD

Abstract

To date, most studies have focused on the characterization of HIV-1-specific cellular immune responses in the peripheral blood (PB) of infected individuals. Much less is known about the comparative magnitude and breadth of responses in the lymphoid tissue. This study analyzed HIV-1-specific CD8+ T cell responses simultaneously in PB and lymph nodes (LNs) of persons with chronic HIV-1 infection and assessed the dynamics of these responses during antiretroviral treatment and supervised treatment interruption (STI). In untreated chronic infection, the magnitude of epitope-specific CD8+ T cell activity was significantly higher in LNs than in PB. Responses decreased in both compartments during highly active antiretroviral therapy, but this decline was more pronounced in PB. During STI, HIV-1-specific CD8+ T cell responses in PB increased significantly. Enhancement in breadth and magnitude was largely due to the expansion of pre-existing responses in the LNs, with new epitopes infrequently targeted. Taken together, these data demonstrate that HIV-1-specific CD8+ T cells are preferentially located in the LNs, with a subset of responses exclusively detectable in this compartment. Furthermore, the enhanced CD8+ T cell responses observed during STI in chronically infected individuals is largely due to expansion of pre-existing virus-specific CD8+ T cells, rather than the induction of novel responses.

MeSH Terms
Antiretroviral Therapy, Highly Active CD8-Positive T-Lymphocytes/physiology Chronic Disease Clinical Protocols Epitopes/immunology,metabolism HIV Infections/drug therapy,immunology HIV-1/immunology,physiology Humans Lymph Nodes/immunology Male Statistics as Topic Whites
Chemicals
Epitopes
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Altfeld Marcus
Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, MA 02129, USA.
van Lunzen Jan
Frahm Nicole
Yu Xu G
Schneider Claus
Eldridge Robert L
Feeney Margaret E
Meyer-Olson Dirk
Stellbrink Hans-Juergen
Walker Bruce D
References (44)
44 references, click to expand
  1. Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2.
    Antivir Ther. 1998;3(4):209-14 PMID: 10682140
  2. The role of lymphoid organs in the pathogenesis of HIV infection.
    Semin Immunol. 1993 Jun;5(3):157-63 PMID: 8102261
  3. Simian immunodeficiency virus-specific cytotoxic T lymphocytes and cell-associated viral RNA levels in distinct lymphoid compartments of SIVmac-infected rhesus monkeys.
    Blood. 2000 Aug 15;96(4):1474-9 PMID: 10942394
  4. Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay.
    J Virol. 2000 Sep;74(18):8541-9 PMID: 10954555
  5. Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype.
    J Virol. 2000 Oct;74(19):9144-51 PMID: 10982361
  6. Immune control of HIV-1 after early treatment of acute infection.
    Nature. 2000 Sep 28;407(6803):523-6 PMID: 11029005
  7. Early programming of T cell populations responding to bacterial infection.
    J Immunol. 2000 Dec 15;165(12):6833-9 PMID: 11120806
  8. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.
    J Exp Med. 2001 Jan 15;193(2):169-80 PMID: 11148221
  9. Cellular immune responses to HIV.
    Nature. 2001 Apr 19;410(6831):980-7 PMID: 11309628
  10. HIV-specific effector cytotoxic T lymphocytes and HIV-producing cells colocalize in white pulps and germinal centers from infected patients.
    Blood. 2001 May 1;97(9):2695-701 PMID: 11313260
  11. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells.
    Nat Immunol. 2001 May;2(5):415-22 PMID: 11323695
  12. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.
    Science. 1999 Feb 5;283(5403):857-60 PMID: 9933172
  13. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.
    J Exp Med. 1999 Mar 15;189(6):991-8 PMID: 10075982
  14. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.
    J Virol. 1994 Jul;68(7):4650-5 PMID: 8207839
  15. Cytotoxic T-cell memory without antigen.
    Nature. 1994 Jun 23;369(6482):648-52 PMID: 7516038
  16. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.
    J Virol. 1994 Sep;68(9):6103-10 PMID: 8057491
  17. HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes.
    Cell. 1994 Aug 12;78(3):373-87 PMID: 7914835
  18. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.
    J Exp Med. 1995 Apr 1;181(4):1365-72 PMID: 7699324
  19. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.
    Science. 1997 Nov 21;278(5342):1447-50 PMID: 9367954
  20. Accumulation of human immunodeficiency virus-specific cytotoxic T lymphocytes away from the predominant site of virus replication during primary infection.
    Eur J Immunol. 1997 Dec;27(12):3166-73 PMID: 9464802
  21. The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapy.
    J Exp Med. 1998 Mar 16;187(6):949-59 PMID: 9500797
  22. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.
    Science. 1998 Mar 27;279(5359):2103-6 PMID: 9516110
  23. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells.
    Nat Med. 1999 Jan;5(1):34-41 PMID: 9883837
  24. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy.
    J Virol. 1999 Jan;73(1):797-800 PMID: 9847391
  25. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression.
    Nat Med. 1999 May;5(5):518-25 PMID: 10229228
  26. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
    N Engl J Med. 1999 May 27;340(21):1605-13 PMID: 10341272
  27. Control of HIV despite the discontinuation of antiretroviral therapy.
    N Engl J Med. 1999 May 27;340(21):1683-4 PMID: 10348681
  28. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy.
    J Virol. 1999 Aug;73(8):6721-8 PMID: 10400770
  29. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors.
    AIDS Res Hum Retroviruses. 1999 Sep 1;15(13):1219-28 PMID: 10480635
  30. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.
    J Clin Invest. 1999 Sep;104(6):R13-8 PMID: 10491418
  31. Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation.
    Nat Immunol. 2001 May;2(5):423-9 PMID: 11323696
  32. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.
    AIDS. 2001 Jun 15;15(9):F19-27 PMID: 11416734
  33. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.
    AIDS. 2001 Jun 15;15(9):F29-40 PMID: 11416735
  34. Less is more? STI in acute and chronic HIV-1 infection.
    Nat Med. 2001 Aug;7(8):881-4 PMID: 11479610
  35. Vpr is preferentially targeted by CTL during HIV-1 infection.
    J Immunol. 2001 Sep 1;167(5):2743-52 PMID: 11509618
  36. Distribution of functional HIV-specific CD8 T lymphocytes between blood and secondary lymphoid organs after 8-18 months of antiretroviral therapy in acutely infected patients.
    AIDS. 2001 Sep 7;15(13):1653-6 PMID: 11546939
  37. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.
    Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13288-93 PMID: 11687611
  38. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection.
    J Virol. 2001 Dec;75(24):11983-91 PMID: 11711588
  39. Lymph nodes during antiretroviral therapy.
    Curr Opin Infect Dis. 2001 Feb;14(1):17-22 PMID: 11979110
  40. HIV-specific cytotoxic T lymphocytes in seropositive individuals.
    Nature. 1987 Jul 23-29;328(6128):345-8 PMID: 3496541
  41. Lymphatic tissue changes in AIDS and other retrovirus infections: tools and insights.
    Lymphology. 1990 Jun;23(2):85-91 PMID: 2170778
  42. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease.
    Nature. 1993 Mar 25;362(6418):355-8 PMID: 8455722
  43. Cytotoxic effector cell granules recognized by the monoclonal antibody TIA-1 are present in CD8+ lymphocytes in lymph nodes of human immunodeficiency virus-1-infected patients.
    Am J Pathol. 1993 Jun;142(6):1750-8 PMID: 8506945
  44. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death.
    J Clin Invest. 2000 May;105(10):1407-17 PMID: 10811848
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
2002-03-00
Pages
837-43
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC150914
Subset
IM
Grants
NIAID NIH HHS · R01 AI-30914 · United States
NIAID NIH HHS · R01 AI040873 · United States
NIAID NIH HHS · R01 AI-44656 · United States
NIAID NIH HHS · R01 AI-40873 · United States
NIAID NIH HHS · R37 AI-12856-8 · United States
NIAID NIH HHS · R01 AI044656 · United States
NIAID NIH HHS · R01 AI030914 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com